tiprankstipranks
Trending News
More News >
Clene (CLNN)
NASDAQ:CLNN
Advertisement

Clene (CLNN) AI Stock Analysis

Compare
1,101 Followers

Top Page

CLNN

Clene

(NASDAQ:CLNN)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 4o)
Rating:54Neutral
Price Target:
$9.50
▼(-5.00% Downside)
Clene's stock score is primarily impacted by its poor financial performance, characterized by significant losses and negative equity. While technical analysis indicates positive momentum, the company's valuation metrics are weak due to negative earnings. The absence of earnings call insights and corporate events means these factors do not influence the score.
Positive Factors
Innovative Drug Platform
Clene's proprietary nanotechnology platform for developing therapies provides a competitive edge in treating neurodegenerative diseases, potentially leading to breakthrough treatments and partnerships.
Strong Gross Profit Margin
A strong gross profit margin indicates efficient cost management and potential for profitability if revenue growth is achieved, supporting long-term business sustainability.
Strategic Partnerships
Strategic partnerships enhance Clene's research capabilities and financial stability, fostering innovation and potential revenue streams through collaborative efforts.
Negative Factors
Declining Revenue
Significant revenue decline highlights challenges in market penetration and product adoption, potentially impacting long-term growth and sustainability.
Negative Equity
Negative equity indicates financial distress and potential insolvency risks, limiting Clene's ability to secure financing and invest in growth opportunities.
High Net Losses
Substantial net losses reflect ongoing operational challenges and cash burn, necessitating strategic restructuring or capital infusion to ensure long-term viability.

Clene (CLNN) vs. SPDR S&P 500 ETF (SPY)

Clene Business Overview & Revenue Model

Company DescriptionClene Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, primarily targeting conditions such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The company operates in the biotechnology sector, leveraging its proprietary nanotechnology platform to create drug candidates that aim to restore cellular function and improve patient outcomes. Clene’s core products include CNM-Au8, a gold nanocrystal suspension designed to enhance cellular energy metabolism and protect neuronal health.
How the Company Makes MoneyClene generates revenue primarily through the development and commercialization of its therapeutic products. The company makes money by advancing its drug candidates through clinical trials, which can lead to licensing agreements, partnerships with larger pharmaceutical companies, and potential product sales once therapies receive regulatory approval. Key revenue streams include milestone payments from collaborations, royalties on future sales, and funding from government grants or research institutions. Additionally, partnerships with academic institutions and biopharmaceutical firms may provide financial support and shared expertise that enhance its revenue-generating capabilities.

Clene Financial Statement Overview

Summary
Clene is facing considerable financial challenges with declining revenues, high net losses, and negative equity. The substantial operating losses and cash flow issues highlight the need for strategic restructuring or additional capital infusion. The biotechnology sector's inherent risk is amplified by Clene's financial instability.
Income Statement
30
Negative
Clene has experienced significant revenue fluctuations with a decline from $654,000 in 2023 to $342,000 in 2024, reflecting a -47.71% revenue growth rate. The gross profit margin is relatively strong at 79.53%, but the company has negative net profit and EBIT margins due to substantial losses, with a net loss of $39.4 million in 2024.
Balance Sheet
20
Very Negative
The company has a negative stockholders' equity of -$8.86 million, indicating financial distress. The debt-to-equity ratio cannot be calculated due to negative equity, but the high total debt of $20.84 million suggests significant leverage. With equity being negative, the equity ratio is also negative, signaling potential insolvency risks.
Cash Flow
35
Negative
Operating cash flow remains deeply negative at -$21.33 million, with a slightly improved free cash flow position over the year. The free cash flow to net income ratio indicates severe cash burn issues, and financing cash flow has decreased, showing potential challenges in raising capital.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue286.00K342.00K654.00K473.00K723.00K206.00K
Gross Profit230.00K272.00K533.00K447.00K434.00K141.00K
EBITDA-29.64M-33.69M-43.24M-25.21M-8.22M-16.92M
Net Income-29.70M-39.40M-49.50M-15.28M-9.74M-19.28M
Balance Sheet
Total Assets22.13M27.34M52.34M44.49M63.06M68.24M
Cash, Cash Equivalents and Short-Term Investments7.29M12.15M35.00M23.32M50.29M59.27M
Total Debt20.85M20.84M32.16M31.82M24.04M4.32M
Total Liabilities30.68M36.19M38.95M41.26M50.47M67.90M
Stockholders Equity-8.55M-8.86M13.39M3.24M12.60M341.00K
Cash Flow
Free Cash Flow-17.64M-21.34M-30.50M-44.19M-35.96M-19.32M
Operating Cash Flow-17.64M-21.33M-30.17M-39.01M-34.62M-18.93M
Investing Cash Flow-3.00K6.32M-1.50M-10.16M-1.33M-387.00K
Financing Cash Flow3.27M-1.53M42.16M17.25M27.11M69.53M

Clene Technical Analysis

Technical Analysis Sentiment
Positive
Last Price10.00
Price Trends
50DMA
7.21
Positive
100DMA
5.55
Positive
200DMA
4.64
Positive
Market Momentum
MACD
0.57
Negative
RSI
65.31
Neutral
STOCH
82.36
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLNN, the sentiment is Positive. The current price of 10 is above the 20-day moving average (MA) of 8.91, above the 50-day MA of 7.21, and above the 200-day MA of 4.64, indicating a bullish trend. The MACD of 0.57 indicates Negative momentum. The RSI at 65.31 is Neutral, neither overbought nor oversold. The STOCH value of 82.36 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CLNN.

Clene Risk Analysis

Clene disclosed 66 risk factors in its most recent earnings report. Clene reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Clene Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
$20.33B14.63-3.31%3.23%1.93%-12.26%
$100.70M-35.29%45.18%
$42.34M-6.28-422.64%129.20%30.36%
$23.82M-112.22%
$32.52M-44.71%44.85%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
CLNN
Clene
10.00
3.65
57.48%
DYAI
Dyadic International
1.17
0.11
10.38%
AKTX
Akari Therapeutics
0.73
-1.67
-69.58%
ESLA
Estrella Immunopharma
2.46
1.66
207.50%
ANTX
AN2 Therapeutics, Inc.
1.24
0.16
14.81%
CAMP
CAMP4 Therapeutics Corporation
4.03
-6.60
-62.09%

Clene Corporate Events

Private Placements and FinancingRegulatory Filings and Compliance
Clene Enters Equity Distribution Agreement with Canaccord
Neutral
Oct 17, 2025

Clene Inc., a company in the biotechnology sector, has entered into an equity distribution agreement with Canaccord Genuity LLC to sell up to $25 million in common stock. As of October 17, 2025, Clene has filed a prospectus supplement to offer an additional $18.88 million in shares, following previous sales totaling approximately $6.12 million, potentially impacting its financial strategy and market presence.

The most recent analyst rating on (CLNN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
Clene Unveils Promising Clinical Data at ECTRIMS 2025
Positive
Sep 25, 2025

On September 25, 2025, Clene announced new clinical data at the ECTRIMS 2025 meeting, highlighting that their product CNM-Au8 improves brain energy metabolism in multiple sclerosis patients. This announcement could enhance Clene’s positioning in the pharmaceutical industry, potentially impacting stakeholders by showcasing the effectiveness of their treatment in a significant medical condition.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Private Placements and Financing
Clene Expands Equity Distribution to Raise Capital
Neutral
Sep 5, 2025

On April 28, 2025, Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to offer and sell shares of its common stock, aiming to raise up to $25,000,000. By September 5, 2025, the company had already sold shares worth approximately $3,706,213 and filed a prospectus supplement for an additional $6,280,000 of shares, reflecting its ongoing efforts to bolster financial resources.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Clene Inc. Reports Q2 2025 Financial Results
Aug 15, 2025

Clene Inc. is a clinical-stage pharmaceutical company focused on developing novel nanotechnology therapeutics primarily for neurological disorders such as ALS, MS, and Parkinson’s disease. In its latest earnings report for the quarter ended June 30, 2025, Clene Inc. reported a net loss of $7.4 million, a slight improvement from the $6.8 million loss in the same quarter last year. The company’s revenue remains minimal, with total revenue of $27,000 for the quarter, reflecting a decline from the previous year’s $91,000. The company’s operating expenses have decreased, with research and development expenses dropping significantly, contributing to a reduced loss from operations. Clene Inc. continues to face financial challenges with a substantial accumulated deficit and limited cash reserves, raising concerns about its ability to continue as a going concern. The company is actively seeking additional funding through various means to support its operations and advance its drug development programs. Looking ahead, Clene Inc.’s management remains focused on securing the necessary resources to continue its research and development efforts and achieve its strategic goals in the pharmaceutical industry.

Financial DisclosuresPrivate Placements and Financing
Clene Amends Notes and Secures New Financing
Neutral
Aug 14, 2025

On August 13, 2025, Clene Inc. announced amendments to its December 2024 senior secured convertible promissory notes, extending the maturity date to February 13, 2027, and postponing the commencement of monthly principal repayments to September 13, 2026. Additionally, the company entered into a new note purchase agreement with AE Capital Limited and others, issuing $1.5 million in senior secured convertible promissory notes. These financial maneuvers aim to provide Clene with a cash runway into the first quarter of 2026, supporting its ongoing clinical programs. Clene also reported its second quarter 2025 financial results, highlighting a net loss of $7.4 million and cash reserves of $7.3 million as of June 30, 2025. The company is advancing its CNM-Au8 programs for ALS and MS, with significant FDA meetings scheduled for the third quarter of 2025, aiming for a new drug application submission for ALS by the end of 2025.

The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 29, 2025